Ovid Therapeutics (FRA:1OT) Common Stock : €0.07 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Common Stock?

Ovid Therapeutics's quarterly common stock declined from Sep. 2023 (€0.07 Mil) to Dec. 2023 (€0.07 Mil) but then stayed the same from Dec. 2023 (€0.07 Mil) to Mar. 2024 (€0.07 Mil).

Ovid Therapeutics's annual common stock increased from Dec. 2021 (€0.06 Mil) to Dec. 2022 (€0.07 Mil) but then declined from Dec. 2022 (€0.07 Mil) to Dec. 2023 (€0.07 Mil).

Ovid Therapeutics Common Stock Historical Data

The historical data trend for Ovid Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Common Stock Chart

Ovid Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.05

0.06

0.07

Ovid Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.07	0.07	0.07	0.07	0.07

Ovid Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Ovid Therapeutics (FRA:1OT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (FRA:1OT) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

OVID:USA

Address

441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001

Website

https://www.ovidrx.com

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics (FRA:1OT) Headlines

No Headlines